• Lubos Holubec, Jiri Polivka, Lenka Lisnerova, Tereza Kubikova, and Martin Safanda.
• Biomedical Center, Faculty of Medicine in Plzen, Charles University, Pilsen, Czech Republic.
• In Vivo. 2017 May 1; 31 (3): 303-306.

AbstractFebrile neutropenia (FN) is a common and potentially fatal complication of anticancer treatment, particularly in patients receiving myelosuppressive chemotherapy. It has been shown that prophylaxis with granulocyte colony-stimulating factor (G-CSF), especially its pegylated forms, significantly reduces the incidence of FN, the likelihood of chemotherapy dose intensity reduction and, also, the number of hospitalizations due to FN. This review discusses currently published results from clinical trials dealing with FN prophylaxis in routine clinical practice in patients with solid tumors and myeloproliferative malignancies with a focus on lipegfilgrastim, which is the newest modification of the original molecule filgrastim. The discussed results proved that prophylactic administration of lipegfilgrastim can almost eliminate the risk of FN and significantly reduce the risk of chemotherapy (CHT) dose reduction in routine clinical practice in cases of a clear high-risk chemotherapy regimen or in the presence of risk factors (such as age, comorbidities, performance status, etc.) in patients who received chemotherapy with medium risk of FN.Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

17 keywords...

hide…